Teva updates on Lonquex and Granix launches

18 November 2013

Israel-based Teva Pharmaceutical Industries (NYSE: TEVA), best known as the world’s largest generic drugmaker, announced two significant additions to its global oncology biologic portfolio with the recent launches of Lonquex (lipegfilgrastim) and Granix (tbo-filgrastim) Injection, and an update on the review status of balugrastim by the US Food and Drug Administration.

Teva launched Lonquex (long-acting G-CSF) in Germany on November 4, the first launch as part of a European Union-wide approval. Teva plans to continue the roll-out of Lonquex across additional countries covered by the European Marketing Approval over the coming months.

Lonquex is a competitor to Amgen’s (Nasdaq: AMGN) Neulasta (pegfilgrastim) and Neupogen (filgrastim), the combined 2102 sales of which were $5.4 billion in 2012.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK